The release of stronger-than-expected jobs data led to a lackluster session on Wall Street, as investors worried that the Federal Reserve would have additional runway to enact an aggressive plan to raise interest rates. The major averages: finished Friday’s trading mixed, with the Nasdaq and S&P 500 posting modest losses and the Dow eking out a slim gain.
Amid the choppy action, iRobot (NASDAQ:IRBT:) represented a standout performer. Boosted by a merger deal with Amazon (AMZN), the stock jumped nearly 20%.
Cytokinetics (CYTK) also pushed significantly higher, rising to a 52-week high in the wake of its quarterly report.
Turning to some of the day’s notable decliners, Warner Bros. Discovery (WBD) posted a double-digit percentage decline following the release of its financial figures. Meanwhile, Hyzon Motors (HYZN) plummeted to a new 52-week low on news of an internal investigation into some of its accounting.
iRobot (IRBT) surged 19% after agreeing to be acquired by online retail giant Amazon (AMZN) in a deal valued at $1.7B.
Under the terms of the transaction, each IRBT share will be exchanged for $61 in cash. After completion of the deal, iRobot CEO Colin Angle will continue as the venture’s chief executive.
IRBT finished Friday’s action at $59.54, a rise of $9.55 on the day. The advance added to an upswing the stock has seen since hitting a 52-week low of $35.41 in late June.
Even with the post-merger advance, IRBT remains about 13% lower for 2022 as a whole.
Warner Bros. Discovery (WBD) succumbed to a massive downdraft following the release of its earnings statement. Dragged down by the messy post-merger quarter, the stock plunged nearly 17%.
The media giant reported a quarterly loss of $3.42B. That included $2B in amortization of intangibles and a $1B charge related to restructuring and other items. The bottom line was also impacted by $983M in transaction and integration costs related to the merger of Discovery and Warner Bros.
WBD dropped $2.89 to close at $14.59. The slide reversed some of the gains posted in the last few weeks. The stock reached a two-month high going into its quarterly release.
Notable New High:
The release of earnings news prompted buying in Cytokinetics (CYTK). The stock rose nearly 11% to reach a new 52-week high.
The biotech reported a quarterly loss that came in significantly narrower than analysts had predicted. The firm also reduced its projected spending for 2022 and added that it expects to end 2022 with more than $800M in cash, enough to fund its operations for two to three years.
Following the earnings release, CYTK got off to a slow start on Friday but surged in the middle of the day to reach an intraday 52-week high of $52.69. The stock moderated late in the session, eventually closing at $51.82. This represented an advance of $5.10 compared to the previous close.
The uptick took the stock past a previous high set in June. The stock has climbed 63% over the past 12 months.
Notable New Low:
A delayed earnings report and the launch of an internal investigation caused shares of Hyzon Motors (HYZN) to crater to a new 52-week low. The stock dropped 38% on the day.
The company announced that it was delaying its earnings report and said its board of directors had appointed a committee to probe certain accounting matters. These related to revenue recognition timing and internal controls/procedures, primarily stemming from its China operations.
HYZN finished at $2.78, a decline of $1.71 on the session. During the day, the stock also reached an intraday 52-week low of $2.47.
Friday’s retreat reversed a recent upswing for the stock, adding to the weakness shown earlier in the year. For 2022 as a whole, HYZN has lost about 60% of its value.
To see more of Wall Street’s biggest winners and losers, turn to Seeking Alpha’s On The Move section.